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Abstract
In a previous issue of Arthritis Research and Therapy, Ursum and
colleagues report the relative stabilities of anticitrullinated protein/
peptide antibodies (ACPAs) and IgM rheumatoid factors during the
course of rheumatoid arthritis and their differential correlation with
markers of the acute-phase response. These findings add to a
growing body of evidence highlighting the distinct nature of these
two autoantibody systems and the role of ACPAs as a disease-
specific marker of rheumatoid arthritis.
In a previous issue of Arthritis Research and Therapy, Ursum
and colleagues report data showing that the anticitrullinated
protein/peptide antibody (ACPA) status is significantly more
stable than that of IgM rheumatoid factors (RFs) during the
course of rheumatoid arthritis (RA) [1] – a finding that is fully
consistent with previous reports [2]. They also found that the
frequency of ACPA positivity is unrelated to age in RA
patients and in the few ACPA-positive patients with non-RA
disease, whereas RF positivity displayed age-related increases
in patients with non-RA disease and it was also more closely
correlated with acute-phase inflammatory markers. These
findings, which are based on serological studies in over
18,000 patients attending outpatient rheumatology clinics,
add to a steadily growing body of evidence highlighting the
distinct natures of these two autoantibody systems.
Differential accuracy in the diagnosis of RA
ACPAs are considered the most accurate serological marker
for RA [3]. ACPA seropositivity is rarely detected in non-RA
patients, although it is occasionally associated with psoriatic
arthritis, tuberculosis, leprosy, and autoimmune hepatitis, and
its specificity for RA (over 96% when measured with second-
generation ELISA) [4] is clearly superior to that of RF. In
contrast, IgG RF, IgA RF, or IgM RF are a frequent finding in
patients with other autoimmune disorders, in those with
infectious diseases (where its prevalence depends on the
primary/secondary nature of the infection, as well as on its
duration), and even in healthy individuals, especially those
who are elderly. The sensitivity of ACPAs is less impressive
(around 68%) [4], but better results (82%) have been
reported with assays measuring anti-Sa, the subset of
ACPAs directed against modified citrullinated vimentine [5].
Anti-Sa positivity also appears to be a better predictor of
radiographic progression in patients with early RA.
Anticitrullinated protein/peptide antibody
role in synovial injury
Citrullinated proteins originate in the synovium, and ACPAs
are produced in the inflamed synovium by local plasma cells.
ACPAs [6] and ACPA-producing B cells have both been
detected in synovial fluid from RA patients. The central role of
these autoantibodies in the pathogenesis of RA has been
demonstrated in a mouse model [7]. More recently, ectopic
lymphoid structures in the synovia of some RA patients have
been shown to support ongoing production of class-switched
ACPAs [8].
Correlation between anticitrullinated
protein/peptide antibodies and genetic
determinants of RA
The HLA-DRB1 shared epitope alleles are a major genetic
risk factor for RA. Their presence is associated with ACPA-
positive forms of RA, and they also influence the magnitude
of the ACPA response [9]. IgM RF has not been linked to any
of the genetic risk factors for RA.
Temporal characteristics of anticitrullinated
protein/peptide antibodies and RF
expression in RA
ACPAs and RFs are both potential components of the
specific autoantibody response that characterizes the pre-
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clinical phase of RA [10], but ACPA positivity is likely to
develop earlier and its presence may contribute to the
subsequent appearance of RFs [11]. Later, with the onset of
clinical RA, ACPA titers rise as a reflection of immune
response maturation and increasing epitope dominance [12].
Conclusions
Together with the new data of the Ursum group, the findings
discussed above strongly support the view that ACPAs are a
disease-specific marker of RA detectable early in the
preclinical phase of the disease. In contrast, IgM-RF sero-
positivity is generally a somewhat later event, and it is
primarily a reflection of an inflammatory process that amplifies
the tissue injury already underway. As Nowak and Newkirk
have noted, the RF response may well be part of a normal
host defense that – in this particular setting – is transformed
into a threat to tissue integrity [13]. An interesting focus for
future studies would be the characterization of ACPA
(particularly anti-Sa) patterns in RA patients with partial
responses to treatment consisting of the remission of signs
and symptoms of inflammation coupled with ongoing radio-
graphic progression.
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